BOT - Anything but charting, page-9793

I would suggest two things:
1. There isn't really any BP rival in this market. Journey Medical, which sells Qbrexza (arguably the best topical available until Sofdra), is worth less than $100m. Admittedly, there is AbbVie who own Botox, but I think they are in a different market (surgical treatment) and just how much applies to Primary Auxiliary Hyperhidrosis, I don't know, but I imagine it is a very small portion of their business.
2. I have always suspected the market wants certainty around the sales figures. Number of Japan scripts are certainly mind-boggling, but the price differential has people questioning if the US can replicate. Weighed up also against the average total sales for Qbrexza ($25m), the market is yet to be convinced, I would suggest. And this is evident in the various analyst notes that call BOT a $1-$3 stock - it is all based on actual sales.

That said, undoubtedly there is a huge untapped market because the other products simply don't work anywhere near as well as Sofdra has been shown to do in trials. Then we have BOT promoting via their unique Patient Experience Program and telemedicine strategies, followed up with feet on the ground in clinics. With a +$70m war chest at their disposal, you WILL see significant take up, I am certain. THAT's when BP are going to be stepping up I believe. They want certainty.